{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T08:55:38Z","timestamp":1765356938709},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.12558","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T15:34:24Z","timestamp":1622216064000},"page":"e2112558","source":"Crossref","is-referenced-by-count":5,"title":["Assessment of New Molecular Entities Approved for Cancer Treatment in 2020"],"prefix":"10.1001","volume":"4","author":[{"given":"Claire E. P.","family":"Smith","sequence":"first","affiliation":[{"name":"Hematology and Medical Oncology, Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco"},{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"issue":"7","key":"zld210097r1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1200\/OP.20.00275","article-title":"Early impact of COVID-19 on the conduct of oncology clinical trials and long-term opportunities for transformation: findings from an American Society of Clinical Oncology survey.","volume":"16","author":"Waterhouse","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"zld210097r5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ejca.2018.11.012","article-title":"A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology.","volume":"106","author":"Haslam","year":"2019","journal-title":"Eur J Cancer"},{"issue":"2","key":"zld210097r6","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp1107201","article-title":"Reputation and precedent in the bevacizumab decision.","volume":"365","author":"Carpenter","year":"2011","journal-title":"N Engl J Med"},{"key":"zld210097r2","unstructured":"US Food and Drug Administration. FDA Approves First Treatment for COVID-19. Food and Drug Administration news release. Published October 22, 2020. Accessed December 4, 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19"},{"key":"zld210097r3","unstructured":"Hahn? SM (@SteveFDA). As we make progress in our understanding of #COVID19, we continue full speed ahead on our non-COVID cancer-related work, including important drug approvals. For instance, as of Oct. 30, the @US_FDA has approved 42 novel drugs including 15 new drugs to treat patients with various forms of cancer. Several of these approvals have been \u201cfirsts\u201d for oncology. November 17, 2020. Accessed April 15, 2021. https:\/\/twitter.com\/stevefda\/status\/1328800222449979392"},{"key":"zld210097r4","unstructured":"US Food and Drug Administration. US Food and Drug Administration hematology\/oncology (cancer) approvals & safety notifications. Updated April 14, 2021. Accessed December 4, 2020. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/hematologyoncology-cancer-approvals-safety-notifications"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2780442\/smith_2021_ld_210097_1621539689.57747.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T15:34:39Z","timestamp":1622216079000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2780442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":6,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.12558","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,28]]}}}